CHRS
CHRS
NASDAQ · Biotechnology

Coherus Oncology Inc

$2.14
+0.05 (+2.39%)
As of Feb 8, 2:01 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 50.41M 45.49M 44.34M
Net Income -12,744,166 -11,017,037 -10,122,519
EPS
Profit Margin -25.3% -24.2% -22.8%
Rev Growth -0.9% +9.2% +11.8%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 52.08M 52.40M 52.30M
Total Equity 77.23M 72.90M 71.12M
D/E Ratio 0.67 0.72 0.74
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -16,231,640 -13,211,435 -14,610,213
Free Cash Flow -10,845,649 -11,236,120 -8,740,023